Salt Lake City, Utah — Kolosis®, the industry’s leading pure-play surgical biologics company, today announced the addition of APEXecm™ to its growing portfolio of targeted solutions. The launch reflects Kolosis’s approach to portfolio expansion — identifying technologies that address unmet clinical needs and delivering them with the commercial focus and technical expertise that only a dedicated biologics partner can provide.
APEXecm: Purposefully Designed, Clinically Differentiated
APEXecm is a next-generation, 100% allogenic extracellular matrix featuring Kolosis’s proprietary Mini Tile Matrix™ configuration — a novel format engineered to deliver consistent precision, adaptability, and ease of use in demanding surgical environments. Comprised of collagen, proteoglycans, and native ECM structural proteins, APEXecm is designed to protect and support the natural wound healing environment for high-risk surgical patients.
The Mini Tile Matrix format addresses a well-documented need expressed consistently by surgeons across specialties — a solution that performs predictably under the variable conditions of live surgery. APEXecm answers that requirement with a unique configuration that is as intentional as it is innovative.
“APEXecm is exactly the kind of technology Kolosis was built to bring to market — clinically differentiated, purposefully designed, and developed because it represents the best available answer to a need surgeons have clearly defined,” said Collin Begley, Chief Executive Officer of Kolosis BIO. “It reflects our continued commitment to raising the standard for what a dedicated surgical biologics company can deliver.”
The addition of APEXecm further extends a Kolosis portfolio spanning orthobiologics, advanced wound biologics, and novel cardiac surgery solutions — each selected through the same rigorous lens of clinical differentiation and commercial viability.
